Charles (Chuck) Baum

Dr. Baum is the Founder, President and Chief Executive Officer of Mirati Therapeutics and has been a Board member since November 2012. Prior to joining Mirati, Dr. Baum was Senior Vice President for Biotherapeutic Clinical Research within Pfizer’s Worldwide Research & Development division. He was at Pfizer from 2003 to 2012, serving in roles of increasing responsibility, including Vice President, Head of Oncology Development and Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center. He was responsible for the development of Pfizer’s oncology portfolio, including Inlyta, Xalkori and the approval of Sutent. Prior to Pfizer, Dr. Baum was at Schering-Plough where he was responsible for the Phase I-IV development of several oncology compounds, including Temodar. His career has also included academic and hospital positions at Stanford and Emory universities. Dr. Baum serves on the Board of Directors at Poseida Therapeutics, PMV Pharma, Odyssey Therapeutics, and Terremoto Biosciences. He is also on the scientific advisory board at ALX Oncology. Dr. Baum received his M.D. and Ph.D. degrees from Washington University School of Medicine and completed his post-graduate training at Stanford University. Additionally, he has received research support from the National Institutes of Health and the American Cancer Society, published more than 50 peer-reviewed manuscripts and holds a number of patents and patent applications.